The survival period of patients with chronic lymphocytic leukemia is usually around 10 to 30 years. Timely treatment with drugs can prolong the survival period and improve the quality of life. 1. Early and mild chronic lymphocytic leukemia does not cause direct damage to the body and organ function, so the survival period can be up to about 30 years. 2. However, if the patient does not receive timely treatment or medication to control the disease when therapeutic indications arise, which may lead to secondary damage to the immune system or serious complications, the survival period may be shortened to about 10 years. Therefore, timely treatment and regular follow-up are needed. Early stage chronic lymphocytic leukemia does not require special treatment when the condition is stable, and attention to nutrition and regular checkups are sufficient. For chronic lymphocytic leukemia with obvious symptomatic episodes, drugs such as nitrogen mustard phenylbutyrate, ibrutinib or fludarabine can be used. High-dose methylprednisolone or anti-leukocyte differentiation antigen monoclonal antibody treatment can also be used when ineffective. It is recommended that patients receive treatment under the guidance of a physician and undergo regular follow-up to avoid exacerbation of the disease.